https://www.selleckchem.com/pr....oducts/cobimetinib-g
One-year mortality rates were 25.0% implying a 2.4-fold increased risk of death compared to the general population. High anti BP180-autoantibody levels at diagnosis (CI95 1.30-2.89;p=.001), dementia (CI95 1.13-6.72;p=.03), length of hospitalization (CI95 1.16-2.41;p=.01) and age (CI95 1.23-4.19;p=.009) correlated significantly with 1-year mortality. BP180-AAB concentrations of ≥61 U/ml characterized a subgroup of patients with a particular higher risk for early death compared to the general population (CI95 1.81-3.81
Curtir
Comentario
Compartilhar
